Key result
Preventive anticoagulation with daily of Enoxaparin in 65 adult patients with nephrotic syndrome resulted in no observed thrombotic events and a low incidence of bleeding.
Why the study?
Does enoxaparin prevent thrombotic complications in adult patients with nephrotic syndrome?
Cohort (n=65)
Does enoxaparin prevent thrombotic complications in adult patients with nephrotic syndrome?
Enoxaparin 40 mg daily appears safe, effective, and well-tolerated for the prevention of thrombotic complications in adult patients with nephrotic syndrome.
Answers are grounded in this paper and cite their sources.
May support enoxaparin prophylaxis in nephrotic syndrome; leaves open confirmation in randomized trials.
The nephrotic syndrome (NS) carries one of the highest risks of thrombotic complications. Consequently, over the last 15 years, some nephrologists have treated patients at risk (i.e. those with albuminemia < 20 g/l and membranous nephropathy) with anticoagulants: either subcutaneous heparin (Kakkar protocol) or antivitamin K. Low-molecular-weight heparin (LMWH) has a longer plasma half-life and better bioavailability than standard heparin and can thus be administered as a single daily injection. LMWH also carries a lower risk of hemorrhage. We prospectively studied the safety and efficacy of the LMWH Enoxaparin for preventive anticoagulation in NS. In a preliminary study, 10 adult nephrotic patients with biological markers of thrombosis risk (severe hypoalbuminemia and/or anomalies of the fibrinolytic pathway and/or deficiency in coagulation inhibitors) were given 40 mg (4,000 U) of Enoxaparin daily for at least 3 months; 3 patients were treated for 3 months, 1 for 6 months and 6 for 12 months. Patients were assessed for silent thrombosis, using renal vein Doppler ultrasonography, lower leg vein Doppler ultrasonography and lung ventilation-perfusion scintigraphy, before entry to the trial and subsequently at 3-month intervals. As LWMH caused no obvious side effects and no thrombosis was observed during the pilot study, we then placed 55 adult nephrotic patients free of thrombosis on the same treatment. Patients were seen according to the usual calendar required by their individual illnesses. At each examination, patients were assessed for clinical signs and symptoms of thrombosis and side effects; plasma D-dimer and urinary fibrin-fibrinogen degradation products were also measured at each visit. Twenty-five of the 55 patients (minimal-change disease, n=15; membranous nephropathy, n=2; systemic lupus erythematosus, n=2; other forms of glomerulonephritis, n = 6) received LMWH for less than 4 months. No side effects or thrombosis were observed, with the exception of 1 patient who had local intolerance to Enoxaparin but not to Teldeparin. The other 30 patients (membranous nephropathy, n=14; segmental glomerulosclerosis, n = 13; other nephropathies, n=3) received LMWH for at least 6 months (median, 13 months; range, 6-48 months). No side-effects or thrombosis were observed. Enoxaparin caused no changes in bone density in patients at risk of osteoporosis, as determined by absorptiometry. The self-administered LMWH therapy was well accepted by patients, most of whom found it straightforward and painless. The results of this prospective study suggest that the LMWH Enoxaparin given at a dose appropriate for adult NS patients with a high thrombotic risk is safe, effective and easily self-administered. The incidence of bleeding was low. Our findings provide arguments for the adoption of LMWH as first-line preventive anticoagulation in NS.
No takes yet. Share an insight, caveat, or question.
Rostoker et al. (2008) conducted a cohort in Nephrotic syndrome (n=65). Enoxaparin was evaluated on Thrombosis and side effects. Preventive anticoagulation with daily of Enoxaparin in 65 adult patients with nephrotic syndrome resulted in no observed thrombotic events and a low incidence of bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: